Table 2.
Extracted information for meta-analyses.
| Study ID, intervention, trial stage | Treatment | N | Change in weekly SBMs | SBMs within 24 hrs | Time to first SBMs | Change in weekly CSBMs | |||
|---|---|---|---|---|---|---|---|---|---|
| Mean | SE∗ | % | Mean | SE∗ | Mean | SE∗ | |||
| Fukudo 2019, linaclotide, III [7] | Placebo | 88 | 1.48 | 0.32 | 48.30 | 24.67 | 3.15 | 0.78 | 0.23 |
| Linaclotide 5 mg | 91 | 4.02 | 0.31 | 72.80 | 6.71 | 3.35 | 2.46 | 0.23 | |
|
| |||||||||
| Fukudo 2018, linaclotide, II [8] | Placebo | 80 | 1.91 | 0.35† | — | — | — | 1.10 | 0.30† |
| Linaclotide 0.0625 mg | 82 | 3.89 | 0.35† | — | — | — | 2.16 | 0.30† | |
| Linaclotide 0.125 mg | 71 | 3.11 | 0.35† | — | — | — | 2.23 | 0.30† | |
| Linaclotide 0.25 mg | 72 | 3.87 | 0.35† | — | — | — | 2.53 | 0.35† | |
| Linaclotide 0.5 mg | 76 | 3.85 | 0.35† | — | — | — | 2.48 | 0.35† | |
|
| |||||||||
| Kumagai 2018, elobixibat, I [9] | Placebo | 10 | 1.40 | 0.57† | 40.00 | — | — | — | — |
| Elobixibat 2.5 mg | 10 | 5.90 | 0.92† | 100.00 | — | — | — | — | |
| Elobixibat 5 mg | 10 | 8.50 | 0.79† | 100.00 | — | — | — | — | |
| Elobixibat 10 mg | 10 | 9.20 | 1.49† | 100.00 | — | — | — | — | |
| Elobixibat 15 mg | 9 | 9.50 | 1.43† | 100.00 | — | — | — | — | |
| Elobixibat 20 mg | 9 | 14.70 | 1.23† | 88.90 | — | — | — | — | |
|
| |||||||||
| Nakajima 2018a, elobixibat, III [10] | Placebo | 63 | 1.70 | 0.20 | 41.00 | 25.50 | 11.63 | 0.60† | 0.20† |
| Elobixibat 10 mg | 69 | 6.40 | 0.60 | 86.00 | 5.10 | 1.80 | 3.30† | 0.50† | |
|
| |||||||||
| Nakajima 2018b, elobixibat, II [11] | Placebo | 40 | 2.60 | 0.46† | 48.00 | 36.20 | 5.72† | 1.50 | 0.22† |
| Elobixibat 5 mg | 43 | 3.50 | 0.55† | 61.00 | 19.90 | 3.03† | 2.00 | 0.32† | |
| Elobixibat 10 mg | 39 | 5.70 | 0.67† | 90.00 | 8.20 | 1.31† | 3.40 | 0.58† | |
| Elobixibat 15 mg | 41 | 5.60 | 0.55† | 93.00 | 8.50 | 1.33† | 3.80 | 0.55† | |
|
| |||||||||
| Fukudo 2015, lubiprostone, III [6] | Placebo | 62 | 1.26 | 0.23 | 30.60 | 48.03 | 10.83† | — | — |
| Lubiprostone 48 μg | 62 | 3.66 | 0.36 | 58.10 | 23.53 | 3.33† | — | — | |
|
| |||||||||
| Fukudo 2011, lubiprostone, II [5] | Placebo | 42 | 1.50 | 0.40 | 26.20 | — | — | — | — |
| Lubiprostone 16 μg | 41 | 2.30 | 0.40 | 53.70 | — | — | — | — | |
| Lubiprostone 32 μg | 43 | 3.50 | 0.50 | 53.50 | — | — | — | — | |
| Lubiprostone 48 μg | 44 | 6.80 | 1.10 | 75.00 | — | — | — | — | |
|
| |||||||||
| Kasugai 2019, lactulose, II [12] | Placebo | 62 | 2.05 | 0.28† | 35.50 | 27.98 | 5.92 | — | — |
| Lactulose 13 g | 63 | 2.17 | 0.26† | 47.60 | 24.50 | 3.36 | — | — | |
| Lactulose 26 g | 63 | 3.77 | 0.38† | 65.10 | 10.00 | 2.73 | — | — | |
| Lactulose 39 g | 62 | 5.05 | 0.65† | 67.70 | 10.33 | 4.28 | — | — | |
CI: confidence interval; CSBM: complete spontaneous bowel movement; hrs: hours; SBM: spontaneous bowel movement. ∗If SEs were not reported, they were calculated from SDs or 95% CIs. †Obtained from figures.